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Background: Melanoma of esophagus (ME) is a rare type of melanoma, accounting for
<3% of cases. Patients with advanced melanoma of esophagus origin, tend to have
lower response rates on traditional therapies. Thus, we report our experience with 11
patients with advanced esophageal melanoma who received PD-1 inhibitors.
Methods: A retrospective analysis of 77 patients with advanced ME were conducted
from the database of Peking University Cancer Hospital between Jan 2008 and Sep
2017. We collected the clinical data and assessed objective response rates (ORR) and
progression–free survival (PFS). The data cutoff date was Jan 1st 2018.
Results: We identified the 77 patients were unresectable or metastatic esophageal mela-
nomas. The Median age was 57, with 67.5% being male. 78% patients had history of
esophagectomy and 64 patients had received prior systemic therapy. There were 8
(10.4%) patients harbored C-KIT mutations and 5 (6.5%) harbored BRAF. We divided
the patients into 3 cohorts according to different treatments: Chemotherapy (C: 8
DTIC/26 TMZ/ 23 PTX; 57 cases), Targeted therapy (T: 6 imatinib/3 vemurafenib; 9
cases) or PD-1 inhibitors (P, 11 cases). The PFS were 3.0 and 4.2 months with limited
ORR of 5.7% and 25.0% respectively for C and T cohort. In the P cohort, 7/11 patients
(63.6%) achieved PR and other 3 remained SD> 4þmonths. The PFS for the P cohort
was 13.0þmonths. Toxicities were as expected and were usually grade 1or 2.
Conclusions: Although this cohort of patients was small, it was the largest report for
now. To our knowledge this is also the first report of outcomes of PD-1 inhibitors in
advanced esophageal melanomas. The dramatic response appears to be an available
option for patients with advanced esophageal melanomas.
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Background: Mucosal melanoma is rare and an aggressive malignancy with poor
response compared with cutaneous melanoma. The prospective trial on immune-check-
point inhibitors in unresectable or metastatic mucosal melanoma has not been reported
except pooled analysis. The aim of this phase II trial was to assess the efficacy and safety
of nivolumab monotherapy for unresectable or metastatic mucosal melanoma.
Methods: Eligibility criteria were as follows: histological diagnosis of unresectable or
metastatic mucosal melanoma; age  20 years; ECOG performance status 0 or 1; and
with measurable lesions. Patients received nivolumab 2 mg/kg every 3 weeks. The pri-
mary endpoint was response rate (RR) according to Response Evaluation Criteria in
Solid Tumors version 1.1( 20%). The secondary endpoints were overall survival, pro-
gression-free survival, disease control rate, and toxicity.
Results: A total of 20 patients were enrolled between December 2014 and July 2017.
Two patients without measurable lesion were excluded from analysis of efficacy. The
RR was 22%, suggesting that the primary endpoint was met. One patient achieved a
complete response, three patients achieved partial response, and six patients achieved
stable disease as their best response. The median progression-free survival was 1.4
months (95% CI, 1.15 to 5.47). The median overall survival was 12.03 months (95% CI,
3.50 to not reach). The 1-year overall survival data was 52.6% (95% CI, 28.5 to 72.0).
Treatment-related adverse events of grade 3 or 4 occurred in 15% (3/20) of the patients.
Grade 3 diarrhea was observed in two patients and grade 3 adrenal insufficiency was
observed in one patient. They were resolved by corticosteroid.
Conclusions: Although this trial met the primary endpoint, the RR was still unsatisfac-
tory. Therefore, the further treatment development is required.
Clinical trial identification: UMIN000015845.
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Background: Anti-PD1 antibodies (aPD1s) for advanced melanoma have proven
their superiority over chemotherapy and ipilimumab in phase III trials. However, in
real-world many patients were not represented in these trials. We report real-world
outcomes of aPD1 for advanced melanoma.
Methods: Pts with advanced (non-uveal) melanoma from 2014 to 2016 who received
1st line aPD1 were selected from the Dutch Melanoma Treatment Registry - a popula-
tion based registry in the Netherlands. Outcomes of pts normally eligible (ELI) for trial
participation (ECOG PS of 0-1, no brain metastasis, auto-immune disease, HIV, psy-
chiatric disorder or corticosteroid use) were compared to pts normally non-eligible (N-
ELI) for trial participation. Time to event was estimated with Kaplan-Meier method
and overall survival (OS) with cox regression analysis.
Results: In total 552 patients with advanced melanoma received 1st line aPD1. Median
age was 65yrs (range 21-94). At baseline 28% had elevated LDH, 90% ECOG PS of 0-1,
19% brain metastases, 65% stage IV-M1c disease and 41% had a BRAF mutation.
Toxicity grade 3-4 occurred in 68 pts (12.3%). Median follow-up estimated with
reverse Kaplan-Meier method was 18.8 mo (95%CI: 18-20). 1- and 2-yr OS (95%CI)
was 72% (68-76%) and 59% (55-65%) and median OS was not reached. Median time
to next treatment (TTNT) for ELI pts was not reached and TTNT for N-ELI pts was
10.6 mo (95%CI: 8.3-14.7). Median time of treatment duration was 8.8 mo (95%CI:
6.9-10.5) for ELI pts and 5.3 mo (95%CI: 4.1-7.1) for N-ELI pts. 1- and 2-yr OS were
respectively 76% (72-81%) and 63% (57-70%) versus 65% (95%CI: 59-72%) and 53
(95%CI: 45-61% (log-rank test p-value: 0.003). Unadjusted hazard ratio (HR) for OS
was 1.57 (95%CI: 1.17-2.09) for N-ELI compared to ELI pts and adjusted HR was 1.28
(95%CI: 0.94-1.73). HR for LDH>500 UI/L was 2.10 (95%CI: 1.23-3.58) and HR for
BRAF neg. pts 1.74 (95%CI: 1.26-2.41).
Conclusions: Real-world outcomes of 1st line aPD1s in patients with advanced mela-
noma seem to be in accordance to results observed in phase III trials. These data sup-
port that N-ELI pts normally not represented in phase III trials may benefit from aPD1
treatment. LDH>500 UI/L and BRAF neg. status were associated with poorer survival.
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Background: Brain metastases are frequent in patients with melanoma and stereotactic
radiotherapy is one of the main treatment options. We report the efficacy and safety of
hypofractionated stereotactic radiation therapy (HFSRT) and stereotactic radiosurgery
(SRS), and its role in melanoma brain metastasis management.
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